New targets and new drugs for hepatobiliary cancers. Read more about New targets and new drugs for hepatobiliary cancers.
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. Read more about Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study. Read more about Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study.
Granulomatous hepatitis, a mystery solved. Read more about Granulomatous hepatitis, a mystery solved.
Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study. Read more about Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study.
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Read more about Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation. Read more about Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation.
Evidence and choice: The BCLC vision for tailoring clinical decision-making. Read more about Evidence and choice: The BCLC vision for tailoring clinical decision-making.
AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. Read more about AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation.
Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation. Read more about Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation.
